Skip to main content
SpringerLink
Log in

Impact of dyslipidemia on estimated glomerular filtration rate in apparently healthy children and adolescents: the CASPIAN-V study

  • Original Article
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

Chronic kidney disease (CKD) is a leading risk factor for development of cardiovascular disease (CVD). Dyslipidemia is also known as risk factor for CVD development. However, the association of dyslipidemia with glomerular injury among healthy children and adolescents remains controversial. We aimed to investigate the relationship between estimated glomerular filtration rate (eGFR) and lipid profile risk factors among healthy children and adolescents.

Methods

In this nationwide survey, 3808 participants (1992 males, 1816 females), aged 7–18 years, were selected by cluster random sampling method from 30 provinces in Iran. Body mass index (BMI) and systolic and diastolic blood pressures were measured. Blood samples were obtained for serum creatinine, fasting blood glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) determinations. GFR was estimated using Schwartz equation.

Results

Girls had higher eGFR than boys (P = 0.04). In a multiple regression analysis, eGFR demonstrated a positive correlation with systolic blood pressure, BMI, fasting glucose, TC, HDL-C, and TG. By the analysis of covariance, TC, HDL-C, and TG showed a negative correlation with eGFR after adjustments for BMI, systolic and diastolic blood pressures, and fasting glucose (OR = 0.56, 95% CI = 0.29–0.89).

Conclusion

The study showed that dyslipidemia is associated with reduced eGFR among the healthy children and adolescents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.

    Article  Google Scholar 

  2. Assadi F. The epidemic of chronic kidney disease: the danger of skepticism. J Nephropathol. 2012;15:61–4.

    Article  Google Scholar 

  3. Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–7.

    Article  Google Scholar 

  4. Anaverka NS, McMurray JJ, Velazques EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.

    Article  Google Scholar 

  5. Bazyluk A, Malyszko J, Zbroch E. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment? Postgrad Med. 2018;130:461–9.

    Article  Google Scholar 

  6. Weaver DJ, Mitsnefes M. Cardiovascular disease in children and adolescents with kidney disease. Semin Nephrolol. 2018;38:559–69.

    Article  Google Scholar 

  7. Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18:29–40.

    Article  CAS  Google Scholar 

  8. Bermudez-Lopez M, Arroyo D, Bertriu A, Masana L, Fernandez E, Valdivielso JM. New perspectives on CKD-induced dyslipidemia. Expert Opin Ther Targets. 2017;21:967–76.

    Article  CAS  Google Scholar 

  9. Khandelwal P, Murugan V, Hari S, Lakshmy R, Hari P, Bagga A. Dyslipidemia: carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2016;31:1313–20.

    Article  Google Scholar 

  10. Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol. 2015;30:2073–84.

    Article  Google Scholar 

  11. Hu PJ, Wu MY, Lin TC, Wu YC, Su SL, Lu KC, et al. Effect of statin on renal function in chronic kidney disease patients. Sci Rep. 2018;8:6276.

    Article  Google Scholar 

  12. Milolasevic I, Zutellia M, Mavrinac V, Orlic L. Dyslipidemia in chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.

    Article  Google Scholar 

  13. Koulouridis E, Georgealidis K, Kostimpa I, Koulouridis I, Krokida A, Houliara D. Metabolic syndrome risk factors and estimated glomerular filtration rate among children and adolescents. Pediatr Nephrol. 2010;25:491–8.

    Article  Google Scholar 

  14. Kuma A, Uchino B, Kawashima M, Enta K, Tamura M, Outsuji Y, et al. Impact of low-density lipoprotein cholesterol in estimated glomerular filtration rate in apparently healthy young to middle-aged men. Clin Exp Nephrol. 2018;22:15–27. 

    Article  CAS  Google Scholar 

  15. Ahadi Z, Bahreynian M, Qorbani M, Heshmat R, Motlagh ME, Shafiee G, et al. Association of anthropometric measures and cardio-metabolic risk factors in normal-weight children and adolescents: the CASPIAN-V study. J Pediatr Endocrinol Metab. 2018;31:747–54.

    Article  Google Scholar 

  16. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45–60.

    Article  Google Scholar 

  17. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 30140:e20171904.

    Article  Google Scholar 

  18. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.

    Article  Google Scholar 

  19. Cases A, Coll E. Dyslipidemia and progression of renal disease in chronic renal disease patients. Kidney Int Suppl. 2005;99:S87–93.

    Article  CAS  Google Scholar 

  20. Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy; comparison with apoprotein C-III. Kidney Int. 2003;63:217–27.

    Article  Google Scholar 

  21. Wj Cain, Milar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein. J Lipid Res. 2005;46:2681–91.

    Article  Google Scholar 

  22. Vazirin ND, Wang XQ, Liang K. Secondary hyperparathyroidism down regulates lipoprotein lipase expression in chronic renal failure. Am J Phys. 1997;273:F925–30.

    Google Scholar 

  23. Assadi F. The growing epidemic of hypertension among children and adolescents: a challenging road ahead. Pediatr Cardiol. 2012;33:1013–20.

    Article  Google Scholar 

  24. Assadi F. Childhood hypertension: a problem of epidemic proportion. Int J Prev Med. 2012;25:473–80.

    CAS  Google Scholar 

  25. Kelishadi R, Gorbani M, Assadi F, Motlag ME, Djalalnia S, Shahsavari A, et al. Glomerular hyperfiltration as a predictor of cardiometabolic risk factors among children and adolescents The childhood and adolescent surveillance and prevention of adult-V study. Int J Prev Med. 2018;9:33.

    Article  Google Scholar 

  26. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9:129–69.

    Article  Google Scholar 

  27. Jellinger PS, Handelsman Y, Rosenbilts PD, Bloomgarden ZT, Fonesca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary. Endocr Pract. 2017;23(Suppl 2):1–87.

    Article  Google Scholar 

  28. Safdar O, Al sharif S, Kari A. Pediatric CKD and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets. 2014;14:177–84.

    Article  Google Scholar 

  29. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825–33.

    Article  CAS  Google Scholar 

  30. Assadi F. Strategies to reduce the incidence of chronic kidney disease in children: a time of action. J Nephrol. 2013;26:41–7.

    Article  Google Scholar 

  31. Apple LJ, Champagne CM, Harsha DW, Cooper LS, Obarzaneck E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–93.

    Google Scholar 

Download references

Acknowledgements

The authors are thankful to the large team working on this study and all participants who made this experience possible.

Funding

This study was funded by Isfahan University of Medical Sciences, as part of a national school-based surveillance program (Project code# 194049).

Author information

Authors and Affiliations

  1. Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

    Mohammad Moafi

  2. Department of Pediatric Nephrology, Rush University Medical Center, 445 E. North Water Street, Suite 1804, Chicago, IL, 60611, USA

    Farahnak Assadi

  3. Department of Epidemiology, Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Ramin Heshmat

  4. Department of Biostatistics, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

    Mehri Khoshhali

  5. Department of Epidemiology, Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

    Mostafa Qorbani

  6. Department of Pediatrics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Mohammad E. Motlagh

  7. Bureau of Family, Population, Youth and School Health, Ministry of Health and Medical Education, Tehran, Iran

    Razieh Dashti

  8. Population, Youth and School Health, Ministry of Health and Medical Education, Tehran, Iran

    Majzoubeh Taheri

  9. Pediatrics Department, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

    Roya Kelishadi

Authors
  1. Mohammad Moafi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farahnak Assadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramin Heshmat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehri Khoshhali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mostafa Qorbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad E. Motlagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Razieh Dashti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Majzoubeh Taheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roya Kelishadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MM, FA, and RH contributed to the study design, data collection, and editing the manuscript. MK contributed to the study concept, statistical analysis, drafting and editing the manuscript. MQ contributed to the study design, data collection, and editing the manuscript. MEM, RD, and MT contributed to conducting the study and editing the manuscript. RK contributed to the study design, conducting the study, drafting, and editing the manuscript. All authors reviewed and approved the final version of manuscript to ensure the accuracy and integrity of the submitted work.

Corresponding author

Correspondence to Farahnak Assadi.

Ethics declarations

Ethical approval

The study was approved by the Isfahan University of Medical Sciences Ethical Committee on human experimentation (Project code# 194049) and was conducted in accordance with the Helsinki Declaration of 1964, as revised in Brazil 2013.

Conflict of interest

No financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moafi, M., Assadi, F., Heshmat, R. et al. Impact of dyslipidemia on estimated glomerular filtration rate in apparently healthy children and adolescents: the CASPIAN-V study. World J Pediatr 15, 471–475 (2019). https://doi.org/10.1007/s12519-019-00270-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-019-00270-2

Keywords

Search

Navigation